Stockscreener 앱 받기
1.35
1.50%
0.02
시간 외 거래:
1.37
0.02
+1.48%
전일 마감가:
$1.33
열려 있는:
$1.35
하루 거래량:
727.57K
Relative Volume:
0.61
시가총액:
$92.30M
수익:
$525.00K
순이익/손실:
$-44.76M
주가수익비율:
-2.0295
EPS:
-0.6652
순현금흐름:
$-37.46M
1주 성능:
+3.85%
1개월 성능:
-12.34%
6개월 성능:
-52.96%
1년 성능:
-66.83%
1일 변동 폭
$1.3049
$1.43
1주일 범위
$1.23
$1.43
52주 변동 폭
$1.16
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.35 | 90.93M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 개시 | Noble Capital Markets | Outperform |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2025-06-24 | 개시 | Jefferies | Hold |
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – FWB:XE7C - TradingView
CRDF Q1 2026 Earnings: EPS Miss Sends Mixed Signals Despite Modest Stock GainPerformance Review - dars.gov.et
Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary - Quartr
Price to earnings forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
Price to earnings forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Price to book forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
CRDFCardiff Oncology Inc Dividends - Finviz
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Dynamic Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Completeness Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2500 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000E Value Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Cardiff Oncology | 4: Statement of changes in beneficial ownership of securities-Director TANNENBAUM RENEE P - Moomoo
Cardiff Oncology | 4: Statement of changes in beneficial ownership of securities-Director PACE GARY W - Moomoo
Cardiff Oncology, Inc. Actuals & Estimates (NASDAQ:CRDF) - TradingView
Cardiff Oncology, Inc. Actuals & Estimates (FWB:XE7C) - TradingView
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Actuals & Estimates (LS:A2P4GU) - TradingView
CRDF Forecast — Price Target — Prediction for 2027 - TradingView
CRDF Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress Remains FocusLong-Term Guidance - dars.gov.et
CRDF News | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Cardiff Oncology director Gary Pace buys $36,600 in stock By Investing.com - Investing.com Australia
CRDF: Phase II Update; Survival Advantage Extended - scr.zacks.com
Cardiff Oncology director Gary Pace buys $36,600 in stock - Investing.com UK
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock By Investing.com - Investing.com Nigeria
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock - Investing.com
Form 4 Cardiff Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan
Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares - Stock Titan
Cardiff Oncology (CRDF) Stifel 2025 Healthcare Conference Summary - Quartr
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology (CRDF) director receives 40,565 stock options at $1.59 strike - Stock Titan
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cardiff Oncology Inc 주식 (CRDF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
275,000 |
673,750 |
1,330,676 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
5.60%
0.04%
자본화:
|
볼륨(24시간):